There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ChemoCentryx (CCXI) and Oncolytics Biotech Inc (ONCY) with bullish sentiments.
ChemoCentryx (CCXI)
In a report issued on November 9, Michelle Gilson from Canaccord Genuity reiterated a Buy rating on ChemoCentryx, with a price target of $20. The company’s shares opened today at $9.52.
According to TipRanks.com, Gilson is ranked #561 out of 4883 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ChemoCentryx with a $15.83 average price target, implying a 66.3% upside from current levels. In a report issued on November 9, H.C. Wainwright also maintained a Buy rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
Oncolytics Biotech Inc (ONCY)
RBC Capital analyst Douglas Miehm reiterated a Buy rating on Oncolytics Biotech Inc yesterday. The company’s shares opened today at $2.58, close to its 52-week low of $2.41.
According to TipRanks.com, Miehm ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.3% and a 43.8% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, CRH Medical Corporation, and Shire.
The word on The Street in general, suggests a Hold analyst consensus rating for Oncolytics Biotech Inc.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
